Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Conivaptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 known ✓ | P30518 | 16/20 | 0.74 |
| ▸ | AVPR1A known ✓ | P37288 | 13/20 | 0.74 |
| ▸ | OXTR | P30559 | 1/20 | 0.58 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Conivaptan SCHEMBL29406590 | 0.99 | AVPR2 (0.75) | AVPR2AVPR1AOXTRAVPR1B | |
| Conivaptan SCHEMBL4625101 | 0.99 | AVPR2 (0.75) | AVPR2AVPR1AOXTRAVPR1B | |
| Hydrochloric Acid SCHEMBL6988764 | 0.95 | AVPR2 (0.67) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6987926 | 0.94 | AVPR2 (0.68) | AVPR2AVPR1AOXTRAVPR1B | |
| Hydrochloric Acid SCHEMBL6993820 | 0.91 | AVPR1A (0.61) | AVPR2AVPR1AOXTR | |
| SCHEMBL5516287 | 0.91 | AVPR2 (0.63) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL13696611 | 0.91 | AVPR2 (0.63) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6986559 | 0.90 | AVPR1A (0.62) | AVPR2AVPR1AOXTR | |
| Hydrochloric Acid SCHEMBL6992455 | 0.90 | AVPR2 (0.60) | AVPR2AVPR1AOXTR | |
| Hydrochloric Acid SCHEMBL6985748 | 0.90 | AVPR2 (0.60) | AVPR2AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| WO-2025093735-A2 | AGENTS FOR USE IN THE TREATMENT OF TAUOPATHIES | DRUG TARGET IP B.V. (NL) | 2025-05-08 | — | — | WO | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-20250090501-A1 | METHODS OF TREATING GUT MOTILITY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-20 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240074944-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2024-03-07 | — | — | US | claimed |
| US-20230303305-A1 | METHOD AND PACKAGE FOR REDUCING THE DEGRADATION OF A DRUG AND/OR EXCIPIENT, E.G. POLYSORBATE STABILIZER, IN A PHARMACEUTICAL PRODUCT | OAKTREE FUND ADMINISTRATION, LLC | 2023-09-28 | — | — | US | claimed |
| EP-4247316-A1 | POLYMER VIALS HAVING STANDARD EXTERNAL DIMENSIONS AND REDUCED INTERNAL VOLUME | SiO2 Medical Products, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| US-20230285405-A1 | Pharmaceuticals for Treating or Preventing Nidoviruses and Picornaviruses | THE UNIVERSITY OF CHICAGO (US) | 2023-09-14 | — | — | US | claimed |
| US-20100249104-A1 | METHODS FOR USING VASOPRESSIN ANTAGONISTS WITH ANTHRACYCLINE CHEMOTHERAPY AGENTS TO REDUCE CARDIOTOXICITY AND/OR IMPROVE SURVIVAL | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | claimed |
| CN-101808517-A | Methods of using vasopressin antagonists with anthracycline chemotherapeutic agents to reduce cardiotoxicity and/or increase survival | OTSUKA PHARMA CO LTD | 2010-08-18 | — | — | CN | claimed |
| EP-2146721-A2 | METHODS FOR USING VASOPRESSIN ANTAGONISTS WITH ANTHRACYCLINE CHEMOTHERAPY AGENTS TO REDUCE CARDIOTOXICITY AND/OR IMPROVE SURVIVAL | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-01-27 | — | — | EP | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2008144269-A2 | METHODS FOR USING VASOPRESSIN ANTAGONISTS WITH ANTHRACYCLINE CHEMOTHERAPY AGENTS TO REDUCE CARDIOTOXICITY AND/OR IMPROVE SURVIVAL | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-27 | — | — | WO | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080221084-A1 | METHOD FOR REDUCING INFARCTION USING VASOPRESSIN ANTAGONIST COMPOUNDS, AND COMPOSITIONS AND COMBINATIONS THEREFOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-09-11 | — | — | US | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| US-20040219208-A1 | Sustained-release medicines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-04 | — | — | US | claimed |
| EP-1413315-A1 | SUSTAINED-RELEASE MEDICINES | Takeda Chemical Industries, Ltd. (JP) | 2004-04-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249104-A1 | METHODS FOR USING VASOPRESSIN ANTAGONISTS WITH ANTHRACYCLINE CHEMOTHERAPY AGENTS TO REDUCE CARDIOTOXICITY AND/OR IMPROVE SURVIVAL | AVPR2, AVPR1B, AVPR1A | AVPR2 1/4885AVPR1A 3/4885OXTR 254/4885 |
| US-20230285405-A1 | Pharmaceuticals for Treating or Preventing Nidoviruses and Picornaviruses | CTRB1, CMA1, MAN2B1 | AVPR2 1639/4885AVPR1A 1597/4885OXTR 3429/4885 |
| US-20250090501-A1 | METHODS OF TREATING GUT MOTILITY DISORDERS | SI, SLC10A2, FABP2 | AVPR2 1808/4885AVPR1A 2284/4885OXTR 3216/4885 |
| US-20040219208-A1 | Sustained-release medicines | ACE, AGTR2, AGT | AVPR2 527/4885AVPR1A 1199/4885OXTR 665/4885 |
| US-20080221084-A1 | METHOD FOR REDUCING INFARCTION USING VASOPRESSIN ANTAGONIST COMPOUNDS, AND COMPOSITIONS AND COMBINATIONS THEREFOR | AVPR2, WFS1, REN | AVPR2 1/4885AVPR1A 11/4885OXTR 399/4885 |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | AVPR2 1954/4885AVPR1A 2066/4885OXTR 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.